Eric T Fung
Overview
Explore the profile of Eric T Fung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nadauld L, McDonnell 3rd C, Dilaveri C, Klein E, Reid R, Marinac C, et al.
Lancet Oncol
. 2025 Jan;
26(2):165-174.
PMID: 39818231
Background: PATHFINDER was a prospective cohort study of multicancer early detection (MCED) testing in an outpatient ambulatory population. The aim of this study is to report the patient-reported outcomes (PROs)...
2.
Matza L, Howell T, Fung E, Janes S, Seiden M, Hackshaw A, et al.
Pharmacoecon Open
. 2024 Jan;
8(2):263-276.
PMID: 38189869
Introduction: Early cancer detection can significantly improve patient outcomes and reduce mortality rates. Novel cancer screening approaches, including multi-cancer early detection tests, have been developed. Cost-utility analyses will be needed...
3.
Schrag D, Beer T, McDonnell 3rd C, Nadauld L, Dilaveri C, Reid R, et al.
Lancet
. 2023 Oct;
402(10409):1251-1260.
PMID: 37805216
Background: Multicancer early detection (MCED) blood tests can detect a cancer signal from circulating cell-free DNA (cfDNA). PATHFINDER was a prospective cohort study investigating the feasibility of MCED testing for...
4.
Jamshidi A, Liu M, Klein E, Venn O, Hubbell E, Beausang J, et al.
Cancer Cell
. 2022 Nov;
40(12):1537-1549.e12.
PMID: 36400018
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining clinical limit of detection...
5.
Gelhorn H, Ross M, Kansal A, Fung E, Seiden M, Krucien N, et al.
Patient
. 2022 Jul;
16(1):43-56.
PMID: 35844011
Background: Emerging blood-based multi-cancer early detection (MCED) tests can detect a variety of cancer types across stages with a range of sensitivity, specificity, and ability to predict the origin of...
6.
Nadauld L, McDonnell 3rd C, Beer T, Liu M, Klein E, Hudnut A, et al.
Cancers (Basel)
. 2021 Jul;
13(14).
PMID: 34298717
To examine the extent of the evaluation required to achieve diagnostic resolution and the test performance characteristics of a targeted methylation cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test, ~6200...
7.
Chen X, Dong Z, Hubbell E, Kurtzman K, Oxnard G, Venn O, et al.
Clin Cancer Res
. 2021 Jun;
27(15):4221-4229.
PMID: 34088722
Purpose: We recently reported the development of a cell-free DNA (cfDNA) targeted methylation (TM)-based sequencing approach for a multi-cancer early detection (MCED) test that includes cancer signal origin prediction. Here,...
8.
Sharma M, Kantorovich S, Lee C, Anand N, Blanchard J, Fung E, et al.
J Psychiatr Res
. 2017 Feb;
89:65-72.
PMID: 28182962
Objective: Pain levels are a key metric in clinical care. However, the assessment of pain is limited to basic questionnaires and physician interpretation, which yield subjective data. Genetic markers of...
9.
Xu J, Margol A, Shukla A, Ren X, Finlay J, Krieger M, et al.
Front Oncol
. 2015 Sep;
5:191.
PMID: 26380221
Medulloblastoma, the most common malignant brain tumor in children, occurs with increased frequency in individuals with Fanconi anemia who have biallelic germline mutations in BRCA2. We describe an 8-year-old child...
10.
Pfundt R, Kwiatkowski K, Roter A, Shukla A, Thorland E, Hockett R, et al.
Genet Med
. 2015 Apr;
18(2):168-73.
PMID: 25880438
Purpose: The prevalence of developmental disabilities in the United States is reported to be 13.87% across all racial, ethnic, and socioeconomic groups. Microarrays have been recommended as first-tier tests for...